Filing Flows › Lifecore Biomedical (LFCR) › Q1 FY27 › vs Q1 FY27
Lifecore Biomedical (LFCR) Q1 FY27 vs Q1 FY27 (quarter over quarter)
Lifecore Biomedical's revenue fell $8.8M (-26%) from $34.2M in Q1 FY27 to $25.3M in Q1 FY27. The biggest changes: HA manufacturing −$11.1M (-59%); CDMO +$2.2M (+14%).
Lifecore Biomedical, Q1 FY27: revenue $25.3M (-19% year over year), operating margin -3.5%, net loss $40.1M, operating cash flow $6.9M. The chart draws each line against Q1 FY27, the increases inside each band.
Margins
| Q1 FY27 | Q1 FY27 | Change | |
|---|---|---|---|
| Free cash flow margin | 23.8% | -7.9% | +31.7 pts |
Every line
| Line | Q1 FY27 | Q1 FY27 | Change | % |
|---|---|---|---|---|
| CDMO | $17.8M | $15.6M | $2.2M | +14% |
| HA manufacturing | $7.5M | $18.6M | −$11.1M | -59% |
| Revenue | $25.3M | $34.2M | −$8.8M | -26% |
| Net loss | $40.1M | $6.2M | $33.9M | +551% |
| Costs & expenses | $65.4M | $40.3M | $25.1M | +62% |
| Operating costs | $26.2M | $31.6M | −$5.4M | -17% |
| Interest & other, net | $39.1M | $8.7M | $30.4M | +350% |
| Income tax | $51K | $23K | $28K | +122% |
| Cost of revenue | $18.5M | $22.1M | −$3.6M | -16% |
| Research & development | $1.4M | $1.5M | −$116K | -8% |
| SG&A | $6.3M | $8.0M | −$1.7M | -21% |
| Operating cash sources | $47.0M | $4.0M | $43.1M | 12× |
| Depreciation | $2.4M | $2.5M | −$105K | -4% |
| Share-based compensation | $1.7M | $2.1M | −$370K | -18% |
| Working capital & other | $42.9M | −$633K | $43.5M | — |
| Net loss absorbed | $40.1M | $6.2M | $33.9M | +551% |
| Operating cash flow | $6.9M | −$2.2M | $9.1M | — |
| Free cash flow (OCF − capex) | $6.0M | −$2.7M | $8.7M | — |
| Capital expenditures | $912K | $513K | $399K | +78% |
Questions
How much did Lifecore Biomedical's revenue grow quarter over quarter in Q1 FY27?
Lifecore Biomedical's revenue fell $8.8M (-26%) from $34.2M in Q1 FY27 to $25.3M in Q1 FY27.
What drove Lifecore Biomedical's revenue change in Q1 FY27?
HA manufacturing −$11.1M (-59%); CDMO +$2.2M (+14%).